Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2014 and presents the new breakdown of its share capital pursuant to the capital increase with preferential subscription rights completed in March 2014.

Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding

Paris, France | Posted on May 12th, 2014

Activity

The revenue recorded by NANOBIOTIX during the first quarter of 2014 corresponds to the upfront payment (pro-rata share) received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract. This licensing contract was signed with PharmaEngine in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region. The total upfront payment totaled €810,640 and is apportioned using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region which is anticipated as 2017.

During the quarter, the most significant event has been a capital increase with preferential subscription rights. The subscription ratio was 3 new shares for 14 existing shares at a subscription price of €10.60 per share. The capital increase was successfully completed on 20 March 2014 and the total amount raised was €28.1 million, after full exercise of the extension clause. The settlement-delivery and the trading of the new shares occurred on 24 March 2014. The rationale for raising these funds was mainly to support the acceleration of the product pipeline.

The company believes that the coming year is going to be a pivotal one for its development, in particular with respect to operational and clinical progress.

New composition of Nanobiotix shareholding structure following the capital increase which took place in March 2014

Following the completion of the capital increase, the original institutional shareholders remaining invested in the company represent 30.2% of its capital. A great number of new shareholders have acquired shares, with a significant increase of retail shareholders (43.6% of the capital against 13.1% previously), and with the arrival of a large number of foreign (non-French) institutional investors (79 shareholders representing 10.7% of the capital compared to 2% previously) mainly from Belgium, the Netherlands, Luxemburg and Italy.

Although the capital increase has resulted in an increase in the number of French institutional investors (from 4 to 30), their aggregate proportion decreased from 15% to 8.2%.

In total, institutional investors represent 49.1% of the capital.

Next financial press release: revenue for the second quarter of 2014, on July 11, 2014

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information, please click here

Contacts:
Nanobiotix
Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55



NewCap.
Financial communication and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53



Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59
/


Instinctif Partners
Media relations (Outside France)
Melanie Toyne Sewell / Katherine Lynch
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Fish-Inspired Material Changes Color Using Nanocolumns March 18th, 2019

New method to reduce uranium concentration in contaminated water March 18th, 2019

Converting biomass by applying mechanical force Nanoscientists discover new mechanism to cleave cellulose effectively and in an environmentally friendly way March 15th, 2019

Exotic “second sound” phenomenon observed in pencil lead: At relatively balmy temperatures, heat behaves like sound when moving through graphite, study reports March 15th, 2019

Nanomedicine

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia March 11th, 2019

New optical imaging system could be deployed to find tiny tumors: Near-infrared technology pinpoints fluorescent probes deep within living tissue; may be used to detect cancer earlier March 8th, 2019

Computer-designed vaccine elicits potent antibodies against RSV: The nanoparticle platform for this respiratory syncytial virus study will be applied to vaccine research on flu, HIV, and more; Seattle startup Icosavax will advance related clinical trials March 8th, 2019

CEA-Leti Breakthrough Opens Path to New Vaccine for HIV: Lipidots Platform Strengthens Immune Response to Protein That Is Key to HIV Vaccine; Results Presented in Nature Publishing Group’s npj Vaccines February 27th, 2019

Announcements

Fish-Inspired Material Changes Color Using Nanocolumns March 18th, 2019

New method to reduce uranium concentration in contaminated water March 18th, 2019

Converting biomass by applying mechanical force Nanoscientists discover new mechanism to cleave cellulose effectively and in an environmentally friendly way March 15th, 2019

Exotic “second sound” phenomenon observed in pencil lead: At relatively balmy temperatures, heat behaves like sound when moving through graphite, study reports March 15th, 2019

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results January 25th, 2019

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 5, 2019 January 18th, 2019

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018 October 29th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project